Trial Outcomes & Findings for The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic Kidney Disease (NCT NCT02133534)

Results Overview

Improvement of endothelial cell (EC) dysfunction will be assessed by improved counts of endothelial progenitor cells.

Recruitment status

TERMINATED

Study phase

PHASE4

Target enrollment

1 participants

Primary outcome timeframe

baseline, 30 days

Results posted on

2014-07-03

Participant milestones
Measure	Atorvastatin Subjects will be treated with atorvastatin 10 mg/day for 30 days. The study team will obtain one blood and urine sample at baseline prior to starting atorvastatin therapy, and again after 30 days of drug therapy. The study team will do ultrasound imaging of the arm in which a probe will be placed over the blood vessels to measure the diameter of the artery and how this changes after a blood pressure cuff is inflated and then deflated. Subjects will take one nitroglycerine tablet during the ultrasound imaging. Atorvastatin
Overall Study STARTED	1
Overall Study COMPLETED	1
Overall Study NOT COMPLETED	0

Withdrawal data not reported

The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic Kidney Disease

Baseline characteristics by cohort
Measure	Atorvastatin n=1 Participants Subjects will be treated with atorvastatin 10 mg/day for 30 days. The study team will obtain one blood and urine sample at baseline prior to starting atorvastatin therapy, and again after 30 days of drug therapy. The study team will do ultrasound imaging of the arm in which a probe will be placed over the blood vessels to measure the diameter of the artery and how this changes after a blood pressure cuff is inflated and then deflated. Subjects will take one nitroglycerine tablet during the ultrasound imaging. Atorvastatin
Age, Customized Greater than 18 Years	1 participants n=5 Participants
Sex: Female, Male Female	1 Participants n=5 Participants
Sex: Female, Male Male	0 Participants n=5 Participants
Region of Enrollment United States	1 participants n=5 Participants

Timeframe: baseline, 30 days

Population: Early termination because of insufficient accrual. With only one study participant, data could not be analyzed.

Improvement of endothelial cell (EC) dysfunction will be assessed by improved counts of endothelial progenitor cells.

Outcome data not reported

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Adverse event data not reported

Adverse event data not reported

Duke University Medical Center

Phone: 919 681 6819